Current treatments for asthma
Pro Research Analysisby 
Searched over 200M research papers
Standard Asthma Treatments: Inhaled Corticosteroids and Bronchodilators
The mainstay of current asthma treatment includes inhaled corticosteroids and β2-adrenoceptor agonists. Inhaled corticosteroids are the most effective anti-inflammatory agents for controlling chronic asthma and reducing airway inflammation, while β2-agonists are the most effective bronchodilators for rapid relief of symptoms and for managing acute asthma attacks. Long-acting β2-agonists are often combined with corticosteroids for sustained symptom control, especially in patients with nocturnal or persistent asthma. These combination inhalers are considered the gold standard for asthma therapy due to their effectiveness and safety profile when used correctly 1569.
Additional Conventional Therapies: Theophylline, Cromones, Leukotriene Modifiers, and Anticholinergics
Other drugs used in asthma management include theophylline, which acts as a bronchodilator and may have immunomodulatory effects, though it requires careful monitoring due to potential side effects. Cromones (such as cromolyn) are mainly used for mild asthma but require frequent dosing. Leukotriene modifiers represent a newer class of oral medications that are less effective than corticosteroids but can be useful as add-on therapy. Anticholinergic agents are more commonly used in chronic obstructive pulmonary disease (COPD) but may have a role in some asthma cases, particularly for acute exacerbations 156.
Biologic Therapies for Severe and Refractory Asthma
For patients with severe asthma that remains uncontrolled despite standard therapy, biologic treatments have become increasingly important. These therapies include monoclonal antibodies targeting specific immune pathways, such as:
- Omalizumab (anti-IgE)
- Mepolizumab, reslizumab, and benralizumab (anti-IL-5 or IL-5 receptor)
- Dupilumab (anti-IL-4/IL-13 receptor)
These biologics have been shown to improve asthma control, reduce exacerbations, and decrease the need for oral corticosteroids in selected patients, particularly those with eosinophilic or allergic asthma phenotypes. The choice of biologic depends on the patient’s specific asthma endotype and biomarkers 2378+1 MORE.
Emerging and Future Therapies: Targeting New Pathways
Research is ongoing to develop new therapies that target upstream inflammatory pathways in asthma. These include monoclonal antibodies against “alarmins” such as thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33), which are released from airway epithelial cells and play a key role in initiating inflammation. These emerging treatments may benefit patients with both type 2 (T2-high) and non-type 2 (T2-low) asthma, addressing unmet needs in patients who do not respond to current biologics 34710.
Personalized Medicine and Phenotype-Driven Treatment
Asthma is a heterogeneous disease with different phenotypes and endotypes, meaning that not all patients respond the same way to treatments. Recent advances focus on identifying treatable traits and using biomarkers to guide therapy, especially for severe asthma. This personalized approach helps match patients to the most effective treatments, including targeted biologics, and is a key area of ongoing research and clinical practice 57810.
Conclusion
Current asthma treatments are highly effective for most patients and include inhaled corticosteroids, β2-agonists, and other conventional therapies. For severe or refractory asthma, biologic therapies targeting specific immune pathways have significantly improved outcomes. Ongoing research into new biologics and personalized treatment strategies continues to expand options for patients, especially those with difficult-to-treat asthma. Despite these advances, there remains a need for therapies that can address all asthma phenotypes and provide long-term disease modification 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic